載入...
Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies
Background: The topical α2 adrenergic receptor agonist brimonidine gel 0.33% is an effective and safe pharmacological treatment for the facial erythema of rosacea. However, adverse events of worsened redness have occasionally been reported with its use. Objective: A detailed analysis of adverse even...
Na minha lista:
發表在: | J Clin Aesthet Dermatol |
---|---|
Main Authors: | , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Matrix Medical Communications
2015
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4557848/ https://ncbi.nlm.nih.gov/pubmed/26345379 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|